NextCell Pharma AB*, parent company of QVance, proudly supports QVance’s newly announced partnership with Royale International. This collaboration, which combines Royale International’s global expertise in logistics with QVance’s innovative quality control solutions, strengthens the supply chain for cell and gene therapies across Europe.
This partnership perfectly complements QVance’s existing collaboration with bioMérieux, a global leader in diagnostic equipment and consumables. Together, these partnerships position QVance as a comprehensive service provider, bringing together top-tier solutions in both critical quality control systems and end-to-end logistics.
"At NextCell Pharma, we recognize the importance of building strong collaborations to drive the safe and reliable delivery of advanced therapies," said Dr. Mathias Svahn, CEO of NextCell Pharma AB. "With Royale International and bioMérieux as partners, QVance is uniquely positioned to address the complex needs of the cell and gene therapy sector."
The new partnership will be showcased during QVance’s launch at ATMP Sweden in Malmö today, marking an important milestone in QVance’s mission to support innovation in advanced therapies.
* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL
For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Websites:
NextCell Pharma AB: www.nextcellpharma.com
QVance AB: www.qvance.se
Cellaviva Sverige: www.cellaviva.se
Cellaviva Danmark: www.cellaviva.dk
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma
Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.
About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell is also a 100% owner of the daughter company, QVance which will offer quality control analytics for advanced therapy developers.